The new device promises faster, more efficient cardiac procedures while maintaining the safety and effectiveness clinicians expect
Cyble’s 2026 healthcare threat report flags a sharp rise in Asia-focused ransomware, with hospitals, elderly care, and diagnostic systems increasingly in cybercriminal crosshairs
Opioid dependence remains a major driver of death and disease worldwide
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Sharp increase in diabetes, hypertension and fatty liver in 30–50 age group
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Subscribe To Our Newsletter & Stay Updated
